Clinical evaluation of heart safety for diacetyl hexamethylene diamine (CAHB) in patients with myelodysplastic syndrome (MDS)

Objective: To observe and evaluate the heart safety of diacetyl hexamethylene diamine (CAHB) applied to the patients with myelodysplastic syndrome (MDS). Methods: 10 patients with MDS were treated with CAHB by continuous intravenous infusion for 2 courses. The indexes to evaluate the heart safety, e. g. adverse reaction, vital sign, myocardium markers, electrocardiogram (ECG), ultrasonic cardiogram, dynamic electrocardiogram were used in pro-, midst-, and post- of every single course. Results: 10 patients with MDS were totally treated for 18 courses. The ECG changes of ventricle depolarization and repolarization, e. g. U wave occurrence, ST segment depression, T wave flatness were detected in 2 patients. No symptoms, no signs, no any other laboratory examination abnormality were detected. The ECG changes were repeated in next course, were recovered after 6 days of drug discontinuation. Conclusion: The abnormal ECG change was correlated to the clinical trial drug CAHB, can recover, after drug discontinuation. No significant changes were detected in any other indexes to evaluate the heart safety.